Qingdao Vland Biotech Co Ltd (603739) - Total Assets
Based on the latest financial reports, Qingdao Vland Biotech Co Ltd (603739) holds total assets worth CN¥3.04 Billion CNY (≈ $445.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Qingdao Vland Biotech Co Ltd net assets for net asset value and shareholders' equity analysis.
Qingdao Vland Biotech Co Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Qingdao Vland Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data.
Qingdao Vland Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Qingdao Vland Biotech Co Ltd's total assets of CN¥3.04 Billion consist of 35.9% current assets and 64.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.3% |
| Accounts Receivable | CN¥405.26 Million | 13.6% |
| Inventory | CN¥188.95 Million | 6.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥131.13 Million | 4.4% |
| Goodwill | CN¥84.20 Million | 2.8% |
Asset Composition Trend (2014–2024)
This chart illustrates how Qingdao Vland Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603739 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qingdao Vland Biotech Co Ltd's current assets represent 35.9% of total assets in 2024, a decrease from 49.7% in 2014.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 14.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 9.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 13.6% of total assets.
Qingdao Vland Biotech Co Ltd Competitors by Total Assets
Key competitors of Qingdao Vland Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Qingdao Vland Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.08 | 1.10 | 2.72 |
| Quick Ratio | 0.88 | 0.92 | 2.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥85.94 Million | CN¥105.96 Million | CN¥469.43 Million |
Qingdao Vland Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Qingdao Vland Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.38 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -1.7% |
| Total Assets | CN¥2.98 Billion |
| Market Capitalization | $562.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Qingdao Vland Biotech Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Qingdao Vland Biotech Co Ltd's assets decreased by 1.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Qingdao Vland Biotech Co Ltd (2014–2024)
The table below shows the annual total assets of Qingdao Vland Biotech Co Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.98 Billion ≈ $436.21 Million |
-1.75% |
| 2023-12-31 | CN¥3.03 Billion ≈ $443.98 Million |
+17.65% |
| 2022-12-31 | CN¥2.58 Billion ≈ $377.37 Million |
+16.07% |
| 2021-12-31 | CN¥2.22 Billion ≈ $325.11 Million |
+53.07% |
| 2020-12-31 | CN¥1.45 Billion ≈ $212.40 Million |
+13.29% |
| 2019-12-31 | CN¥1.28 Billion ≈ $187.49 Million |
+35.54% |
| 2018-12-31 | CN¥945.32 Million ≈ $138.33 Million |
+6.99% |
| 2017-12-31 | CN¥883.55 Million ≈ $129.29 Million |
+6.72% |
| 2016-12-31 | CN¥827.92 Million ≈ $121.15 Million |
+0.77% |
| 2015-12-31 | CN¥821.63 Million ≈ $120.23 Million |
+3.38% |
| 2014-12-31 | CN¥794.79 Million ≈ $116.30 Million |
-- |
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more